S-1/A: Anteris Technologies Global Corp. Files for U.S. IPO to Advance Heart Valve Technology

Anteris Technologies Global Corp., a structural heart company, has filed for an initial public offering (IPO) in the U.S. to support the development and commercialization of its innovative DurAVR transcatheter heart valve system.

Summary

• Anteris Technologies Global Corp. is seeking to raise capital through a U.S. IPO to fund the development of its DurAVR transcatheter heart valve system.
• The DurAVR system is a single-piece, biomimetic valve designed to improve blood flow and durability for patients with aortic stenosis.
• The company's proprietary ADAPT tissue technology has shown clinical promise with calcium-free results for up to 10 years.
• The IPO aims to support the preparation and enrollment of a pivotal trial for the DurAVR THV system, targeting a market expected to reach $9.9 billion globally by 2028.
• The company is targeting North America and Europe, which are expected to represent $5.5 billion and $3.7 billion of the global market, respectively, in 2028.
• The company has completed an early feasibility study (EFS) with 15 patients, showing promising results in hemodynamics, and is planning to submit an IDE for a pivotal trial to the FDA by Q1 2025.
• The company expects to enroll the first patient in the pivotal trial in the third quarter of 2025.
• The company is currently generating small amounts of revenue and has incurred net losses since inception.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. The technology is promising and the market is large, but the company faces significant financial and operational risks. The sentiment is neutral to slightly negative due to the company's financial situation and the challenges of bringing a new medical device to market.

Positives

• The DurAVR THV system has a novel biomimetic design that aims to replicate the normal blood flow of a healthy human aortic valve.
• The company's proprietary ADAPT tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure.
• The ComASUR delivery system is designed to provide precise alignment with the hearts native commissures to achieve accurate placement of the DurAVR THV system.
• The company has observed promising results in relation to hemodynamics, laminar flow and exercise capacity in its FIH study.
• The company has completed enrollment of 15 patients in its EFS, with positive results at 30 days post-procedure.
• The company has treated six patients in Canada with its DurAVR THV system in a valve-in-valve procedure through a special access program.
• The company has a strong patent portfolio, including 35 issued patents and over 50 pending patent applications.

Negatives

• The company has a history of operating losses and may not achieve or maintain profitability in the future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company will require substantial additional future financing and may be unable to raise sufficient capital.
• The company's products are in development and may not achieve market acceptance.
• The company may find it difficult to enroll patients in its clinical trials.
• The company operates in a highly competitive and rapidly changing industry.
• The company relies on third parties to conduct its clinical trials and preclinical studies.
• The company is subject to various risks relating to international activities.
• The company could become exposed to product liability claims.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company has a history of operating losses and may not achieve or maintain profitability in the future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company will require substantial additional future financing and may be unable to raise sufficient capital.
• Unsuccessful clinical trials or procedures relating to the company's products could have a material adverse effect on its prospects.
• If the company is unable to successfully identify, develop, obtain and maintain regulatory clearance or approval for and ultimately commercialize any of its current or future products, or experience significant delays in doing so, its business may be harmed.
• The company's products are in development and may not achieve market acceptance.
• The company may find it difficult to enroll patients in its clinical trials.
• The company operates in a highly competitive and rapidly changing industry.
• The company relies on third parties to conduct its clinical trials and preclinical studies.
• The company is subject to various risks relating to international activities.
• The company could become exposed to product liability claims.
• The company has identified material weaknesses in its internal control over financial reporting.
• The market price and trading volume of the company's Common Stock may be volatile and may be affected by economic conditions beyond its control.
• An active trading market for the company's Common Stock may not develop and you may not be able to resell your shares of Common Stock at or above the public offering price, if at all.

Future Outlook

The company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, primarily for the ongoing development of DurAVR THV and the preparation and enrollment of the Pivotal Trial of DurAVR THV for treating severe aortic stenosis, with the remaining for working capital and other general corporate purposes.

Management Comments

• The company clinically developed our DurAVR THV system over several years with significant physician input with the goal of addressing hemodynamic limitations of the current standard-of-care products.
• The company is dedicated to developing technological enhancements and new indications for existing products, and less invasive and novel technologies to address unmet patient needs.

Industry Context

The company is operating in a highly competitive and rapidly changing medical technology industry, facing competition from large healthcare companies, academic institutions, and other public and private research organizations. The company is targeting a large, underpenetrated and growing market for TAVR procedures, which is expected to benefit from an aging population, earlier diagnosis of aortic stenosis, and increased incidence of obesity and diabetes.

Comparison to Industry Standards

• The company's DurAVR THV system is designed to address hemodynamic limitations of current standard-of-care TAVR devices, which are typically three-piece valves.
• The company's ADAPT tissue technology has shown clinical promise with calcium-free results for up to 10 years, which is a key differentiator from other TAVR devices.
• The company's ComASUR delivery system is designed to provide precise alignment with the hearts native commissures, which is not consistently achieved in competitive delivery systems.
• The company's FIH study has shown promising results in relation to hemodynamics, laminar flow and exercise capacity, which are key metrics for TAVR devices.
• The company's EFS has shown a mean effective orifice area (EOA) of 2.2 cm2, mean pressure gradient (MPG) of 7.5 mmHg and Doppler velocity index (DVI) of 0.64 at 30 days post-procedure, which are comparable to or better than results from other TAVR devices.

Stakeholder Impact

• Shareholders will be subject to the risks associated with a development stage company, including the possibility of losing their investment.
• Employees will be subject to the risks associated with a development stage company, including the possibility of job loss.
• Customers will benefit from the development of a new and innovative heart valve technology.
• Suppliers will benefit from the company's growth and increased demand for its products.
• Creditors will be subject to the risks associated with a development stage company, including the possibility of not being repaid.

Next Steps

• The company plans to submit an IDE for the DurAVR THV system Pivotal Trial to the FDA by Q1 of 2025.
• The company anticipates enrollment to begin in the third quarter of 2025 for the Pivotal Trial.
• The company expects that the CDIs will commence trading on the ASX on the trading day following the closing of this offering under the symbol AVR.
• The company will de-list its securities from the ASX concurrent with the closing of this offering.

Key Dates

Keywords

transcatheter heart valve, aortic stenosis, DurAVR, ADAPT tissue, TAVR, biomimetic valve, cardiovascular device, medical device, IPO, clinical trial